Market Brief

Intas' Romiplostim Biosimilar to Cut Immune Thrombocytopenia Treatment Cost Sixfold, an Industrial Info Market Brief

India's leading pharmaceutical company, Intas Pharmaceuticals Limited, is taking a step toward making therapy for chronic immune thrombocytopenia (ITP) more affordable to patients by being the first to launch Romiplostim in India under the brand name Romy. With the launch of Romiplostim, cost for treating chronic ITP will come down by almost six times. Intas' biosimilars are manufactured at the company's biotechnology plant in Moraiya in Gujarat. Industrial Info is tracking Intas' manufacturing assets involving oral formulations, injectables and active pharmaceutical ingredients (API) units. Industrial Info database has 831 Pharma-Biotech plant records in India, with more then 3,500 functional management contacts. Click here for a list.

Released Thursday, July 18, 2019